AbbVie’s $11B Apogee Acquisition Brings an Eczema Drug With an Edge

AbbVie is expanding its immunology leadership with a deal to acquire Apogee Therapeutics for $135.11 per share in cash, a roughly 49% premium to Apogee’s price before the announcement and valuing the transaction at about $11 billion. The move brings AbbVie a late-stage eczema therapy that could differentiate on dosing convenience and broaden the company’s reach into respiratory disease.

A Late-Stage Eczema Candidate With Longer Dosing Intervals

Apogee, based in Waltham, Massachusetts, develops biologic therapies against validated inflammatory targets but aims to improve on efficacy, safety, and dosing profiles. Its lead program, zumilokibart, is an IL-13–targeting antibody heading into Phase 3 for atopic dermatitis (eczema). The antibody was engineered with an extended half-life to enable subcutaneous injections as infrequently as every three or six months—far less often than many existing biologics for eczema, which are typically dosed every two to four weeks.

Beyond eczema, Apogee is positioning zumilokibart as a “pipeline-in-a-product,” with mid-stage studies planned in asthma and eosinophilic esophagitis. If successful, the agent could serve patients across multiple type 2 inflammatory conditions with an infrequent dosing schedule designed to improve adherence and convenience.

Building Combination Approaches

Apogee is also developing combinations centered on zumilokibart. APG279 pairs the IL-13 inhibitor with APG990, a half-life–extended antibody targeting OX40L, a costimulatory pathway implicated in allergic and inflammatory responses. This combo is in Phase 1 testing. A second program, APG273, combines zumilokibart with APG333, an antibody directed against TSLP—another key cytokine in airway inflammation. APG273 is in preclinical development for asthma and chronic obstructive pulmonary disease (COPD). AbbVie said the acquisition accelerates its presence in respiratory R&D, complementing its established strengths in immunology.

Strategic Fit With AbbVie’s Immunology Portfolio

Immunology remains AbbVie’s largest therapeutic pillar. Skyrizi, an IL-23 p19–targeting antibody, is approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. AbbVie’s current atopic dermatitis franchise is anchored by Rinvoq, an oral JAK inhibitor. While effective, JAK inhibitors carry boxed warnings related to increased risks of certain malignancies and cardiovascular events. A long-acting biologic alternative like zumilokibart could provide another option for patients and prescribers seeking to minimize frequent dosing and avoid class-wide warnings associated with JAK inhibition.

“The acquisition of Apogee further builds on our existing leadership, strengthening our ability to deliver innovative medicines to patients who need better options while also creating significant long-term value for shareholders,” said AbbVie Chairman and CEO Robert Michael. He added that Apogee’s clinical-stage assets broaden AbbVie’s immunology footprint in high-need areas, including atopic dermatitis and asthma.

Deal Dynamics and Development Acceleration

Analysts noted that while the purchase price is substantial, the fit is strategic: zurmilokibart aligns closely with AbbVie’s expertise in immunology and offers entry points into additional respiratory indications. Apogee recently secured non-dilutive financing via a royalty agreement to support late-stage trials of zumilokibart. By acquiring the company outright, AbbVie can both accelerate Phase 3 development and potentially reduce future royalty obligations tied to that financing.

From Spinout to Strategic Takeout

Apogee was founded in 2022 as a spinout from Paragon Therapeutics, the biologics engine of Fairmount Funds. It was Paragon’s first company to go public, debuting in 2023 at $17 per share before rapidly advancing its IL-13 program and broader combination strategy. The company’s emphasis on long-acting antibodies against well-validated pathways helped it stand out in crowded immunology categories.

Context Within AbbVie’s M&A Track Record

The Apogee acquisition is AbbVie’s largest since 2024, when it completed the $10.1 billion purchase of ImmunoGen to bolster its oncology portfolio with antibody-drug conjugates. AbbVie’s biggest deal remains the $63 billion acquisition of Allergan, which underpins its aesthetics business. The Apogee transaction has been approved by both companies’ boards and is subject to customary regulatory and shareholder approvals. Closing is expected in the third quarter of this year.

What to Watch Next

• Phase 3 initiation and trial design for zumilokibart in atopic dermatitis, including dosing regimens (every three vs. six months) and key efficacy endpoints.
• Progress of the APG279 (IL-13 + OX40L) combination through early clinical stages and initial signals in allergic inflammation.
• Preclinical-to-clinical transition of APG273 (IL-13 + TSLP) in asthma and COPD, and how it aligns with AbbVie’s respiratory ambitions.
• Integration timelines and any updates on re-prioritizing resources across AbbVie’s broader immunology pipeline.

If zumilokibart confirms durable efficacy with ultra-infrequent dosing, it could reset expectations in eczema care and provide AbbVie a differentiated asset that extends well beyond dermatology into respiratory and other type 2 inflammatory diseases.